ProPhase Labs, Inc.
ProPhase Labs develops novel drugs, supplements, and compounds in the US. It operates two segments: Diagnostic Services and Consumer Products. The company offers TK supplements for male sexual health and energy/stamina booster. It also provides contract manufacturing services, COVID-19 diagnostic information, respiratory testing, and personal genomics products. Additionally, it researches, develops, manufactures, and sells OTC consumer healthcare products and dietary supplements.
Overview
Strengths
- Price to book ratio (1.49) is lower than the sector mean (9.96).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Current Price to Earnings Ratio (100.00) is significantly higher than the sector mean (67.88).
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (7.40%).
- EV/EBITDA (100.00) is significantly higher than the sector mean (36.02).
- EV/EBIT (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |